GELAD Chemotherapy and Sandwiched Radiotherapy in the Treatment of Stage IE/IIE Natural Killer/T-cell Lymphoma

Key facts

Sponsor

Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

Principal Investigator

Rong Tao, MD

Xinhua hospital, Shanghai Jiao Tong University of Medicine

Intervention

GELAD(drug)

Enrollment

52 target

Eligibility

15-75 years · All sexes

Timeline

2016 – 2021

Study locations (7)

• Shanghai Dong Fang hospital, Shanghai, Shanghai Municipality, China
• Department of Hematology, Renji Hospital, Shanghai, Shanghai Municipality, China
• South Renji hospital, Shanghai, Shanghai Municipality, China
• Xin Jiang People's Hospital, Ürümqi, Xinjiang, China
• Shanghai Ninth Peoples' Hospital, Shanghai, China
• Shanghai Eye and ENT Hospital of Fudan University, Shanghai, China
• Xinhua Hospital, Shanghai, China

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Extranodal nasal NK/T cell lymphoma

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE2NCT07380984
  PD-1 Antibody-based Therapy With Concurrent RT for Early-stage NKTCL
  Ruijin Hospital
• RECRUITINGPHASE1, PHASE2NCT06966154
  A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL
  Fudan University
• RECRUITINGPHASE2NCT07000617
  A Phase II Study of Dexamethasone, Azacitidine, Pegaspargase and Tislelizumab Plus Radiotherapy for Patients With Stage I/II Extranodal NK/T-cell Lymphoma
  Peking University Cancer Hospital & Institute
• RECRUITINGPHASE1NCT06732492
  RD13-02 Cell Injection in Patients with Relapsed or Refractory CD7-Positive Natural Killer/T Cell Malignancies
  Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
• ENROLLING BY INVITATIONNCT07450040
  Efficacy and Safety of Tislelizumab Combined With Gemcitabine and Peraspartase in the Treatment of Patients With Primary Stage I-II NK/T Cell Lymphoma
  Eye & ENT Hospital of Fudan University
• RECRUITINGPHASE1, PHASE2NCT06559553
  "Selinexor+Pegaspargase+Dexamethasone"in Ⅰ/Ⅱ NKTCL
  Mingzhi Zhang
• RECRUITINGPHASE2NCT06824883
  Sintilimab, Pegaspargase Plus GemOx for Untreated Extranodal NK/T-Cell Lymphoma
  Peking Union Medical College Hospital
• RECRUITINGPHASE1, PHASE2NCT06376721
  Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell Lymphoma
  Beijing Tongren Hospital

See all trials for Extranodal nasal NK/T cell lymphoma →